Therapies of the state

What can governmental agencies do to lower the risk of cell therapies and the enterprises commercializing them?

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Global tissue engineering market.
Figure 2: Timeline of seminal events in cell therapy R&D.

References

  1. 1

    Giebel, L. Stem cells—a hard sell to investors. Nat. Biotechnol. 23, 798–800 (2005).

    CAS  Article  Google Scholar 

  2. 2

    Alliance for Regenerative Medicine. 2014 Regenerative Medicine Annual Industry Report (2014).

Download references

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Schachter, B. Therapies of the state. Nat Biotechnol 32, 736–741 (2014). https://doi.org/10.1038/nbt.2984

Download citation

Further reading